Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma is a phase 2 interventional study registered as NCT03364530 by University Hospital, Montpellier, with a registry enrolment figure of 40 participants, started 2018-06-11 and due to reach its primary completion in 2025-10-21. Interventions recorded: Gemcitabine-Oxaliplatin Regimen, Hepatic intra arterial chemotherapy. Conditions listed: Cholangiocarcinoma Non-resectable, Non-metastatic. Gallbladder cancer is named in the registry entry: "* Patients with cholangiocarcinoma of the gallbladder or common bile duct or those with hepatocholangiocarcinoma or a Klatskin tumor". Sites: France. No results are recorded here; the registry entry is the source.